Corrigendum to “KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis.” Kidney International 2024;105(3S):S71–S116 (Kidney International (2024) 105(3S) (S71–S116), (S0085253823007445), (10.1016/j.kint.2023.10.008))

DOI of original article: 10.1016/j.kint.2023.10.008 The KDIGO Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis Work Group has issued amendments to the supporting text of Practice Point 9.3.1.9 and guideline Figure 12. In the original publication, the supporting text of Practice Point 9.3.1.9 incorrectly cites data from the meta-analysis by Walsh et al. as “absolute risk reduction of 6% in patients with SCr over 5.7 mg/dl (500 µmol/l).” The meta-analysis demonstrated an absolute risk reduction of 16.0% (95% confidence interval: 4.2%–23.6%).¹ Thus, the statement has been revised to “absolute risk reduction of 16% in patients with SCr over 5.7 mg/dl (500 µmol/l). An error was also identified in Figure 12, which incorrectly indicated that higher serum creatinine is a risk factor for increased relapse of ANCA-associated vasculitis. The correct information is that lower serum creatinine is associated with an increased risk of relapse. The corrected figure and the corresponding data reflect that lower serum creatinine levels should be recognized as a significant risk factor for relapse in patients with ANCA-associated vasculitis.²³ We apologize for the oversight and any confusion that may have been caused. The authors sincerely regret these errors and have made the necessary changes to the text and corrections to the figure. The article has been corrected online to reflect these corrections.